iveness studies available to help guide the clinician
to make appropriate decisions on use of these products. Evidence in this expanding ﬁeld will need to be evaluated so
that populations of patients who would beneﬁt the most
from speciﬁc tissue products can be identiﬁed. A signiﬁcant
role for patient-centered outcomes measures also needs to
be incorporated into trial design in the future. The patient’s preferences will need to be balanced with clinical efﬁcacy